Breaking News Bar
updated: 7/17/2013 4:27 PM

Abbott Labs 2Q income falls after AbbVie spinoff

hello
Success - Article sent! close
  • Libertyville Township-based Abbott Laboratories, the largest maker of heart stents and adult nutritional beverages, said second-quarter profit climbed 16 percent as sales increased in emerging markets including Russia and China.

      Libertyville Township-based Abbott Laboratories, the largest maker of heart stents and adult nutritional beverages, said second-quarter profit climbed 16 percent as sales increased in emerging markets including Russia and China.
    Associated Press

 
Associated Press

Libertyville Township-based Abbott Laboratories Inc. said Wednesday that its net income fell in the second quarter following the spinoff of its branded drug business, but the results beat Wall Street expectations

Abbott said sales of nutrition and diagnostic products improved, making up for lower sales of generic drugs and medical devices. The company spun off its branded drug business into a separate company called AbbVie on Jan. 1. AbbVie sells products including the anti-inflammatory drug Humira.

Order Reprint Print Article
 
Interested in reusing this article?
Custom reprints are a powerful and strategic way to share your article with customers, employees and prospects.
The YGS Group provides digital and printed reprint services for Daily Herald. Complete the form to the right and a reprint consultant will contact you to discuss how you can reuse this article.
Need more information about reprints? Visit our Reprints Section for more details.

Contact information ( * required )

Success - request sent close

Abbott said its net income fell to $476 million, or 30 cents per share, from $1.73 billion, or $1.08 per share, a year ago. Excluding one-time charges and last year's AbbVie results, however, its earnings rose to 46 cents per share from 43 cents per share. Analysts surveyed by FactSet expected 44 cents per share.

Revenue grew 3 percent to $5.45 billion from $5.31 billion. Analysts expected $5.52 billion in revenue

Abbott gained less than 1 percent to $35.82 at the close in New York. The shares have increased 14 percent this year.

"We still expect Abbott's sales and earnings per share growth to outpace its MedTech and diversified peers," said Glenn Novarro, an analyst at RBC Capital Markets in New York, in a July 15 note to clients. "Abbott is the fastest-growing large cap company in our universe. As such, a premium valuation is justified."

Abbott retained the original company's medical devices, nutritional products, diagnostic tests and generic drugs. AbbVie, which will report earnings on July 26, kept the brand name drugs, including the best-selling Humira for rheumatoid arthritis.

Abbott backed its guidance for the full year, saying it expects to earn between $1.98 and $2.04 per share excluding special items. Analysts expect $2.01 per share on average.

Share this page
Comments ()
Guidelines: Keep it civil and on topic; no profanity, vulgarity, slurs or personal attacks. People who harass others or joke about tragedies will be blocked. If a comment violates these standards or our terms of service, click the X in the upper right corner of the comment box. To find our more, read our FAQ.